Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
REGENXBIO Inc. (RGNX)
Sector: Healthcare; Industry: Biotechnology

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-02-25 Mills Kenneth T. President and CEO Sell 1,500 $40.77 $61,155 Yes
2021-02-12 Christmas Patrick J. Chief Legal Officer Sell 4,701 $49.08 $230,725 Yes
2021-02-08 Christmas Patrick J. Chief Legal Officer Sell 1,300 $49.11 $63,843 Yes
2021-02-02 Christmas Patrick J. Chief Legal Officer Sell 10,000 $44.79 $447,880 Yes
2021-01-25 Mills Kenneth T. President and CEO Sell 6,500 $44.74 $290,779 Yes
2021-01-15 Vasista Vittal Chief Financial Officer Sell 252 $50.04 $12,610 No
2021-01-14 Simpson Curran Chief Oper. & Tech. Officer Sell 13,312 $50.01 $665,767 Yes
2021-01-14 Vasista Vittal Chief Financial Officer Sell 15,293 $50.02 $765,025 No
2021-01-12 Christmas Patrick J. Chief Legal Officer Sell 21,500 $48.14 $1,035,082 Yes
2021-01-07 Simpson Curran Chief Oper. & Tech. Officer Sell 5,185 $50.01 $259,302 Yes
2021-01-08 Vasista Vittal Chief Financial Officer Sell 16,239 $49.06 $796,615 No
2021-01-07 Mills Kenneth T. President and CEO Sell 1,500 $50.01 $75,015 Yes
2020-12-28 Mills Kenneth T. President and CEO Sell 6,500 $48.67 $316,334 Yes
2020-12-24 Vasista Vittal Chief Financial Officer Sell 24,500 $50.01 $1,225,211 No
2020-12-23 Mills Kenneth T. President and CEO Sell 4,500 $50.00 $225,000 Yes
2020-12-16 Mills Kenneth T. President and CEO Sell 15,000 $45.00 $675,000 Yes
2020-12-11 Vasista Vittal Chief Financial Officer Sell 37,500 $40.10 $1,503,891 No
2020-12-10 Mills Kenneth T. President and CEO Sell 4,500 $40.00 $180,000 Yes
2020-07-15 Vasista Vittal Chief Financial Officer Sell 14,950 $40.10 $599,495 Yes
2020-05-11 Vasista Vittal Chief Financial Officer Sell 7,500 $40.17 $301,260 Yes
2020-04-24 Vasista Vittal Chief Financial Officer Sell 15,000 $40.09 $601,320 Yes
2020-02-11 Simpson Curran SVP, Product Development & CTO Sell 56,993 $50.28 $2,865,636 Yes
2020-02-10 Vasista Vittal Chief Financial Officer Sell 14,806 $50.07 $741,352 Yes
2020-02-10 HAYDEN DONALD J JR Director Sell 24,800 $50.11 $1,242,728 Yes
2020-02-05 Simpson Curran SVP, Product Development & CTO Sell 5,637 $50.00 $281,850 Yes
2020-02-05 Vasista Vittal Chief Financial Officer Sell 300 $50.00 $15,000 No
2020-02-05 HAYDEN DONALD J JR Director Sell 2,000 $50.00 $100,000 Yes
2020-01-17 Simpson Curran SVP, Product Development & CTO Sell 5,922 $50.00 $296,100 Yes
2020-01-17 Vasista Vittal Chief Financial Officer Sell 2,394 $50.00 $119,700 No
2020-01-17 HAYDEN DONALD J JR Director Sell 3,200 $50.01 $160,032 Yes

Insider Smart

VBI Vaccines Inc (VBIV) - Since 10%-owner Perceptive Advisor LCC increased their holding in April, the stock have double the price. Impressive!

Insider Smart

PROSPECT CAPITAL CORP (PSEC) - PSEC is the 2nd most bought stock of the past 90 days by insiders, CEO seems very confident about the company.